Methylene blue

Generic Name: Methylene blue

Brand Names: Hyophen, Phosphasal, Provayblue, Proveblue, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Urogesic Blue Reformulated Apr 2012, Ustell, Utira, Lumeblue (previously known as Methylthioninium chloride Cosmo), Methylthioninium chloride Proveblue

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈ClN_₃S

CAS Number: 61-73-4

Unique Ingredient Identifier: 8NAP7826UB

Background: Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinar...

Indication: Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
...

Associated Conditions: Cystitis, Methemoglobinemia, Nephritis, Urethritis, Urinary tract inflammation

Associated Therapies: Diuresis

Clinical Trials

Methylene Blue and Ozone in Early Sepsis

Phase 4

Conditions: Sepsis

Interventions: Drug: methylene blue
Other: saline infusion
Drug: ozone
Other: oxygen

First Posted Date: 2016-09-22

Last Posted Date: 2016-09-22

Lead Sponsor: Assiut University

Target Recruit Count: 40

Registration Number: NCT02910765

Methylene Blue Against Falciparum Malaria in Burkina Faso

Phase 2

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Primaquine
Drug: Methylene Blue

First Posted Date: 2016-08-01

Last Posted Date: 2020-03-25

Lead Sponsor: Heidelberg University

Target Recruit Count: 100

Registration Number: NCT02851108

Locations: 🇧🇫
CRSN, Nouna, Burkina Faso

Phase 2 Efficacy Study of Primaquine and Methylene Blue

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: Sulphadoxine-pyrimethamine
Drug: Dihydroartemisinin-piperaquine
Drug: Methylene blue
Drug: 0.25 mg/kg primaquine
Drug: Amodiaquine

First Posted Date: 2016-07-13

Last Posted Date: 2017-01-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 80

Registration Number: NCT02831023

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy

Phase 2

Conditions: Periradicular Disease

Interventions: Device: diode laser
Drug: Methylene blue

First Posted Date: 2015-09-21

Last Posted Date: 2015-09-21

Lead Sponsor: Shahid Beheshti University

Target Recruit Count: 20

Registration Number: NCT02555488

Locations: 🇮🇷
Shahid Beheshti University, Tehran, Iran, Islamic Republic of

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

Phase 1

Completed

Conditions: Methemoglobinemia
Congenital Methemoglobinemia

Interventions: Drug: Methylene Blue

First Posted Date: 2015-06-23

Last Posted Date: 2018-01-25

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 12

Registration Number: NCT02478281

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

Phase 2

Conditions: Alzheimer's Disease
Mild Cognitive Impairment
MCI
Aging
AD

Interventions: Drug: FD&C Blue # 2
Drug: Methylene Blue
Drug: Phenazopyridine hydrochloride

First Posted Date: 2015-03-05

Last Posted Date: 2022-08-26

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 117

Registration Number: NCT02380573

Locations: 🇺🇸
Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Methylene Blue Intravenously and Chronic Neuropathic Pain

Not Applicable

Completed

Conditions: Neuropathic Pain

Interventions: Drug: Methylene blue

First Posted Date: 2014-12-01

Last Posted Date: 2014-12-01

Lead Sponsor: Uppsala University

Target Recruit Count: 10

Registration Number: NCT02303886

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

Phase 1

Completed

Conditions: Abscess

Interventions: Drug: Methylene Blue
Drug: 20% I.V. Fat Emulsion
Device: Insertion of optical fiber
Device: Laser illumination, 5 minutes
Device: Laser illumination, 10 minutes
Device: Laser illumination, 15 minutes
Device: Laser illumination, 20 minutes
Device: Laser illumination, 25 minutes
Device: Laser illumination, 30 minutes
Device: Optical spectroscopy measurement

First Posted Date: 2014-09-15

Last Posted Date: 2024-03-06

Lead Sponsor: University of Rochester

Target Recruit Count: 21

Registration Number: NCT02240498

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research

Not Applicable

Completed

Conditions: Sentinel Lymph Node
Breast Cancer

Interventions: Drug: Indocyanine green
Drug: methylene blue

First Posted Date: 2014-03-12

Last Posted Date: 2018-06-07

Lead Sponsor: Chinese Academy of Sciences

Target Recruit Count: 98

Registration Number: NCT02084784

Locations: 🇨🇳
Key Laboratory of Molecular Imaging, Chinese Academy of Sciences, Beijing, Beijing, China

Infrared Lymphangiography as a Method of Sentinel Node Identification

Not Applicable

Completed

Conditions: Melanoma
Sentinel Node

Interventions: Drug: Indocyanine green
Drug: Technetium99
Drug: Methylene blue

First Posted Date: 2014-02-07

Last Posted Date: 2017-07-06

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 89

Registration Number: NCT02057393

Locations: 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy